India, Sept. 1 -- The Mumbai-headquartered pharma major, has struck a notable oncology partnership that pushes it beyond its usual generics and respiratory turf. The exclusive tie-up with China's SBP Group brings a next-generation antibody-drug conjugate into its portfolio, with rights across several emerging markets. Responsibilities are split fairly cleanly: Cipla handles local development and regulatory work, SBP's manufacturing arm keeps production in-house. Coming not long after a mixed Q1FY27 earnings print, the deal offers a hint of where the company's longer-term strategy might be headed.

Shares of Cipla Ltd are trading at Rs. 1411.30, up 0.15 percent on Tuesday. Stock touched the intraday high of Rs. 1425.70 after opening at Rs....